YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ligand Pharmaceuticals JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 20…
Ligand Pharmaceuticals JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate i…
With the tech sector coming under pressure many are looking for alternative investment areas. This pharma stock is an option worth considering. Continue Reading
Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion "Dream Military" budget. Continue Reading
The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals. Continue Reading
Most readers would already be aware that Ligand Pharmaceuticals' (NASDAQ:LGND) stock increased significantly by 16% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on th…
Ligand Pharmaceuticals (LGND) shares have seen a steady climb in recent months, drawing some attention from investors interested in pharmaceutical royalty platforms. With solid gains over the past month, many are starting to analyze what i…
Ligand Pharmaceuticals reported third-quarter 2025 results, showing revenue of US$115.46 million and net income of US$117.27 million, both rising sharply from the previous year, and raised its full-year guidance for core revenue, royalties…
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the…
Orchestra BioMed Holdings, Inc. Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medt…
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) just released its third-quarter report and things are looking bullish. Statutory earnings performance was extremely strong, with revenue of US$115m beating expectations by 99% and earnings…
Ligand Pharmaceuticals Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnin…
Ligand Pharmaceuticals recently announced that CEO Todd Davis and CFO Tavo Espinoza will attend three major healthcare investor conferences in November 2025, including the UBS Global Healthcare Conference, Stifel 2025 Healthcare Conference…
Ligand Pharmaceuticals JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate i…
Ligand Pharmaceuticals JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company…
Ligand Pharmaceuticals JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:3…
Ligand Pharmaceuticals Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (…
In recent days, U.S. stock indexes have shown little movement as investors digest revised jobs data indicating a weaker labor market than previously thought. Amid these conditions, identifying stocks that may be trading below their fair va…
If you have been watching Ligand Pharmaceuticals (LGND), the $400 million convertible note offering completed this month might have made you sit up and pay attention. Not only did the company finalize this sizable senior unsecured notes de…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate i…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior note…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior no…
As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff concerns and economic health. In such a…
Ligand Pharmaceuticals Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earni…
Orchestra BioMed Holdings, Inc. • Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $1…
Ligand Pharmaceuticals JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company w…
Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84. Continue Reading View Comments
Ligand Pharmaceuticals JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™…
Over the last 7 days, the United States market has remained flat, but it has risen by 12% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying undervalued stocks that have not yet caught up…
Channel Therapeutics Corporation The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million eq…
Ligand Pharmaceuticals Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled…
As the U.S. stock market experiences a period of optimism, with major indices like the S&P 500 and Nasdaq reaching their highest levels since February, investors are encouraged by positive inflation data and progress in China-U.S. trade ta…
Ligand Pharmaceuticals JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern T…
Ligand Pharmaceuticals JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Dav…
Ligand Pharmaceuticals (NASDAQ:LGND) First Quarter 2025 Results Key Financial Results Revenue: US$45.3m (up 46% from 1Q 2024). Net loss: US$42.5m (down by 149% from US$86.1m profit in 1Q 2024). US$2.21 loss per share (down from US$4.86 pro…